Evaluating the content validity, clarity and relevance of two patient reported outcomes (PROs) for use with adults with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)
Non-small cell lung cancers (NSCLCs) account for most lung cancers; approximately 30% involve a mutation in the epidermal growth factor receptor (EGFR) gene. This study sought to identify one or more patient reported outcome (PRO) measures relevant for use in clinical trials to assess symptoms and health-related quality of life in this population.
